Attovia Therapeutics IPO: $17 pricing on 2026-08-04
Attovia Therapeutics priced 17,000,000 shares at $17 in its dated 2026-08-04 announcement, with approximately $289.0 million base gross proceeds.
Dated offering terms — 2026-08-04
Attovia Therapeutics announced a price of $17 for 17,000,000 shares, representing about $289.0 million before fees. Its announcement expected Nasdaq Global Market trading under ATTO on 5 August 2026. Closing was expected on 6 August 2026, subject to conditions.
Attovia develops biotherapeutics for immune-mediated diseases. All base shares were offered by the company, and the banks received a 30-day option for 2,550,000 additional shares. This is a dated account of the August financing.
What the financing changes
For an emerging drug developer, the useful comparison is between the program that the proceeds can fund and the evidence needed at the next decision point. Gross offering proceeds are not the same as spendable cash after transaction costs. Scientific differentiation must ultimately be shown in patient data, including efficacy and tolerability. A financing can extend the opportunity to generate that evidence without establishing its outcome. Subsequent company reports should be assessed against the original development objectives.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.